Reduced expression of argininosuccinate lyase is closely associated with postresectional survival in hepatocellular carcinoma: An immunohistochemistry study of 61 cases

Applied Immunohistochemistry and Molecular Morphology

Volumn 20, Issue 6, 2012, Pages 602-606

  Yang, Hua ^a   Zhai, Guojun ^a   Ji, Xiaoxu ^b   Su, Jing ^c   Lin, Ming ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b Departments of Interventional Radiology and Vascular Surgery   (China)

^c PEKING UNIVERSITY THIRD HOSPITAL   (China)

Author keywords

argininosuccinate lyase (ASL); HCC; immunohistochemistry; prognosis; survival

Indexed keywords

ARGININOSUCCINATE LYASE;

ADULT; ARTICLE; CANCER INVASION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION; TUMOR RECURRENCE; TUMOR VOLUME;

ARGININOSUCCINATE LYASE; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84870466968     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e318250c814     Document Type: Article

References (22)

1. Landis SH, Murray T, Bolden S, et al. Cancer statistics, 1998. CA Cancer J Clin. 1998;48:6-29.
2. Bosch FX, Ribes J, Cleries R, et al. Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2005;9:191-211.
3. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 1954;7:462-503.
4. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557-2576.
5. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006;6:674-687.
6. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907-1917.
7. Suriawinata A, Xu R. An update on the molecular genetics of hepatocellular carcinoma. Semin Liver Dis. 2004;24:77-88.
8. Leao-Filho GC, Lopes EP, Ferraz AA, et al. Hepatitis G virus infection in patients with hepatocellular carcinoma in Recife, Brazil. Jpn J Clin Oncol. 2007;37:632-636.
9. Tanaka S, Mogushi K, Yasen M, et al. Surgical contribution to recurrence-free survival in patients with macrovascular-invasionnegative hepatocellular carcinoma. J Am Coll Surg. 2009;208:368-374.
10. IkedaM, Okusaka T, Ueno H, et al. Predictive factors of outcome and tumor response to systemic chemotherapy in patients with metastatic hepatocellular carcinoma. Jpn J Clin Oncol. 2008;38:675-682.
11. Kaibori M, Ishizaki M, Saito T, et al. Risk factors and outcome of early recurrence after resection of small hepatocellular carcinomas. Am J Surg. 2009;198:39-45.
12. Isokawa O, Suda T, Aoyagi Y, et al. Reduction of telomeric repeats as a possible predictor for development of hepatocellular carcinoma: convenient evaluation by slot-blot analysis. Hepatology. 1999; 30:408-412.
13. Yeh MM, Larson AM, Campbell JS, et al. The expression of transforming growth factor-alpha in cirrhosis, dysplastic nodules, and hepatocellular carcinoma: an immunohistochemical study of 70 cases. Am J Surg Pathol. 2007;31:681-689.
14. Shen YC, Hsu C, Cheng AL. Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives. J Gastroenterol. 2010;45:794-807.
15. Wu G, Morris SM Jr. Arginine metabolism: nitric oxide and beyond. Biochem J. 1998;336:1-17.
16. Lam TL, Wong GK, Chong HC, et al. Recombinant human arginase inhibits proliferation of human hepatocellular carcinoma by inducing cell cycle arrest. Cancer Lett. 2009;277:91-100.
17. Kim RH, Coates JM, Bowles TL, et al. Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspaseindependent apoptosis. Cancer Res. 2009;69:700-708.
18. Ascierto PA, Scala S, Castello G, et al. Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J Clin Oncol. 2005;23:7660-7668.
19. Izzo F, Marra P, Beneduce G, et al. Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. J Clin Oncol. 2004;22:1815-1822.
20. Ensor CM, Holtsberg FW, Bomalaski JS, et al. Pegylated arginine deiminase (ADI-SS PEG 20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. Cancer Res. 2002;62:5443-5450.
21. Sukowati CH, Rosso N, Croce LS, et al. Hepatic cancer stem cells and drug resistance: relevance in targeted therapies for hepatocellular carcinoma. World J Hepatol. 2010;2:114-126.
22. Korita PV, Wakai T, Shirai Y, et al. Multidrug resistance-associated protein 2 determines the efficacy of cisplatin in patients with hepatocellular carcinoma. Oncol Rep. 2010;23:965-972.